Navigation Links
Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis
Date:6/17/2008

STUDY TO ASSESS IMPACT OF ELAGOLIX ON BONE MINERAL DENSITY

SAN DIEGO, June 17 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the elagolix 0603 Phase IIb trial (Petal Study) has completed the 6-month treatment phase. The last subject completed her Week 24 study visit in early June. This Phase IIb trial assesses the impact of elagolix treatment on bone mineral density (BMD) as the primary endpoint using Dual Energy X-ray Absorptiometry (DXA) scans to document any change from baseline. In addition, efficacy assessments of endometriosis symptoms using the Composite Pelvic Sign and Symptoms Score (CPSSS) and Visual Analog Scale (VAS) are secondary endpoints.

"The Petal Study is an important trial for the elagolix program," says Christopher O'Brien, MD, Chief Medical Officer and Senior Vice President of Clinical Development. "For the first time we have the opportunity to examine the relationship between estradiol, n-telopeptide (a biomarker for bone resorption), elagolix plasma concentrations and BMD using DXA. We included a positive control, Depo-Provera, as one treatment arm in this randomized, double-blind, active comparator controlled trial to provide confidence that the trial would not miss subtle treatment-related effects," stated Dr. O'Brien.

"The recruitment process for the Petal Study confirms that endometriosis is an important, unmet medical need afflicting many women in the United States. Our call center received over 8,000 calls expressing interest in new treatments for endometriosis," reports Dr. O'Brien. A total of 252 women with endometriosis were randomized to one of three treatment arms: oral elagolix 150mg once daily, oral elagolix 75mg twice daily or Depo-P
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences Reports First Quarter 2008 Results
2. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
3. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
4. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
5. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
6. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
7. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
8. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
9. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
10. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... DALLAS , July 23, 2014 ... LLC ("Plaintiff") filed suit in the 116 ... Dallas, Texas , against RegenLab USA, ... Current and Prospective Business Relationships through false ... interference; and, Business Disparagement through libel, ...
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- Use of Risk Evaluation and Mitigation ... generic market entry results in $5.4 billion in lost ... analysis by economic consulting firm Matrix Global ... Required by the Food and Drug ... programs are intended to improve drug safety by ensuring ...
(Date:7/23/2014)... 2014 PositiveID Corp. (OTCQB: PSID), based in ... an emerging player in the bio-threat detection market, ... and rapid medical testing. The Company,s proprietary airborne ... Networked Detector), was developed under contract with the ... Technology directorate, and $30 million of contract funding. ...
Breaking Medicine Technology:New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry 2PositiveID Analyst Inspection: Emerging Contender in BioThreat Detection - First Ever Revenue Guidance and Backlog Position Company for Increased Visibility and Traction - by SmallCapTraders.com 2
... Requip XL Improved Symptoms in Patients Not Optimally ... "Off" Time by Nearly Two Hours Per Day, ... (NYSE: GSK ) today announced the approval ... for the treatment,of the signs and symptoms of ...
... monotherapy study shows ACTEMRA is first and only biologic to, ... ... treatment -, PARIS, June 13 ... (RA) -- despite treatment with,current therapies -- achieved significant improvements in ...
Cached Medicine Technology:U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 2U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 3U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 4U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 5ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 2ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 3ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 4ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 5ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 6ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 7
(Date:7/23/2014)... July 23, 2014 The beauty products ... by the year 2020, according to recent news reports. ... the top sellers in the U.S. and the CherryNews.com ... cream under $100 is now reviewed at http://cherrynews.com/best-nourishing-eye-serum ... a first-time or experienced shopper to compare the different ...
(Date:7/23/2014)... The age spots, wrinkles and puffy eyes that can be ... now explored in a new guide posted at the Cherry ... over 30 are introduced in the guide as well as ... of creams as an alternative to surgery is one method ... the information in the new guide. Because there are hundreds ...
(Date:7/23/2014)... Recently, iFitDress.com, a professional company of women’s ... 2014 vintage party dresses . Aside from that, it ... discount is up to 63% off. , “We are excited ... new items are all manufactured by trustworthy and experienced workers ... July 30; it is great to provide such a great ...
(Date:7/23/2014)... New York, New York (PRWEB) July 23, 2014 ... that the use of a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ... uterine sarcoma and other cancers throughout a woman’s body, ... on July 22nd in the Journal of the American ... hysterectomy using a power morcellator at 500 U.S. hospitals ...
(Date:7/23/2014)... By Steven Reinberg ... (HealthDay News) -- Many obese and overweight American children ... their weight is fine, U.S. health officials reported Wednesday. ... health outcomes, such as high blood pressure, high cholesterol ... epidemiologist at the U.S. Centers for Disease Control and ...
Breaking Medicine News(10 mins):Health News:Best Wrinkle Cream Under $100 Reviewed at Top News Website Online 2Health News:Best Eye Creams for Women Over 30 Detailed in Published Guide at News Website Online 2Health News:Cheap 2014 Vintage Party Dresses From Professional Supplier iFitDress.com 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3
... seen in older patients, study finds , , THURSDAY, Feb. 26 ... to spike up when men reach their mid-40s. , And ... are startlingly similar to the risk factors seen in older ... have no obvious symptoms but can cause residual damage -- ...
... Coast Service Options (FCSO), one of the nation,s largest ... to implement the second and final phase of a ... the Centers for Medicare and Medicaid Services (CMS) last ... involves Medicare Part A and B administrative services for ...
... a statement by American Heart Association President Timothy Gardner, M.D. ... that President Obama is committed to putting health care reform ... spare. With more than 10,000 Americans losing coverage each day, ... provide affordable care to all Americans. His plan sets us ...
... and Advise Patients from Thousands of Miles AwayWASHINGTON, ... for researchers and scientists working in Antarctica became ... Faculty Associates -- an academic, multi-specialty physician group ... -- completed the installation and testing of a ...
... China Connection Global,Healthcare (CCGH), a pioneering leader ... Experience for Teens, an obesity-intervention plan,designed to ... of,the disease. The eight week summer ... offer 40 US high school students and ...
... lead to additional treatments, experts say , , THURSDAY, Feb. ... as playing a role in the inherited form of amyotrophic ... Massachusetts Medical School and King,s College, London. , The discovery, ... linked to the neurological disorder, also known as Lou Gehrig,s ...
Cached Medicine News:Health News:Men's Stroke Risk Rises Dramatically in Mid-40s 2Health News:Men's Stroke Risk Rises Dramatically in Mid-40s 3Health News:First Coast Service Options Announces Start-up of New Medicare Contract in the U.S. Virgin Islands 2Health News:Remote Medicine: GWU Medical Faculty Treat Antarctica Personnel 2Health News:Medical Tourism Provider Addresses Childhood Obesity through Cultural Immersion, Education 2Health News:Medical Tourism Provider Addresses Childhood Obesity through Cultural Immersion, Education 3Health News:Gene Mutation Linked to Inherited ALS 2
... fast and effective resection of meniscal tears ... rim. The flat, crescent-shaped tip has an ... tightest joint spaces. Made in the U.S. ... engineering experience in arthroscopy hand instrument design ...
... Punch series facilitates fast and effective resection ... anatomically shaped meniscal rim. The flat, crescent-shaped ... access even the tightest joint spaces. Made ... 20 years of engineering experience in arthroscopy ...
... design provides fingertip ratchet disengagement allowing smooth, ... program offers state-of-the-art quality in an instrument ... and durability. Low profile cutting tips allow ... Series I instruments are available in just ...
... design provides fingertip ratchet disengagement allowing smooth, ... program offers state-of-the-art quality in an instrument ... and durability. Low profile cutting tips allow ... Series I instruments are available in just ...
Medicine Products: